Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema (NCT07106268) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema
China100 participantsStarted 2023-03-01
Plain-language summary
the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is:
What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?
Who can participate
Age range20 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage
* Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened
* Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm
* Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery
* The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram
Exclusion Criteria:
* Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation
* Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases
* Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study